Mon panier

Biotinylated Human CD20 Full Length Protein (VLP)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-H82P3-20ug
$930.00
CD0-H82P3-100ug
$1853.00
CD0-H82P3-500ug (250ug X 2)
$6458.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Biotinylated Human CD20 Full Length Protein (VLP) (CD0-H82P3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N82P3) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Labeling

    The VLP is biotinylated with proprietary technology.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Ofatumumab biosimilar with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Obinutuzumab biosimilar with a linear range of 0.2-2 ng/mL (Routinely tested).

    Protocol
  • Identity-DLS

     CD20 DLS

    The mean peak Radius of VLP is 65-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Avis des utilisateurs
Publier un commentaire

Introduction de fond

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD20

  • Catégorie:

  • Nombre de médicaments répertoriés:

    35 Détails

  • Nombre de médicaments cliniques:

    132 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte